Calcitonin

Most Common Uses

Calcitonin is a peptide hormone employed in the treatment of several bone and calcium-related disorders. Its primary applications include managing conditions that affect bone density and calcium levels in the body, typically administered through nasal spray or injection.

Calcitonin is commonly used to treat postmenopausal osteoporosis. By inhibiting osteoclast activity, which are cells responsible for bone breakdown, it helps maintain bone density and reduce the risk of fractures in women after menopause.

Another frequent use is in the management of Paget’s disease of bone. This condition involves abnormal bone remodeling, leading to deformed and weakened bones. Calcitonin helps regulate bone turnover, alleviating pain and improving bone structure in affected patients.

In cases of hypercalcemia, where blood calcium levels are elevated due to factors like cancer or overactive parathyroid glands, Calcitonin is used to lower calcium concentrations. It achieves this by promoting calcium excretion and reducing bone resorption.

Additionally, Calcitonin is sometimes prescribed for pain relief in bone-related conditions, such as fractures or metastatic bone disease. Its ability to modulate bone metabolism can provide comfort and support recovery in these situations.

Mechanism of Action

Calcitonin is a peptide hormone that plays a significant role in regulating calcium and bone metabolism. It is produced primarily by the C-cells of the thyroid gland in response to elevated blood calcium levels. The hormone exerts its effects through specific actions on bone and kidney tissues, contributing to the maintenance of calcium balance in the body.

In bone, Calcitonin acts directly on osteoclasts, the cells responsible for bone resorption. It binds to receptors on the osteoclast surface, inhibiting their activity and reducing the breakdown of bone tissue. This action decreases the release of calcium from bones into the bloodstream, helping to lower blood calcium levels when they are elevated.

In the kidneys, Calcitonin promotes the excretion of calcium and phosphate through urine. It achieves this by influencing renal tubular cells, which enhances the elimination of these minerals. This process further supports the reduction of circulating calcium levels.

Calcitonin’s effects are generally more pronounced in conditions of high bone turnover or elevated calcium levels, such as in hypercalcemia or certain bone disorders. Its rapid action makes it a valuable therapeutic agent in specific medical contexts, complementing other hormones like parathyroid hormone to maintain calcium homeostasis.

Structure and Pharmacology

Calcitonin is a peptide hormone composed of 32 amino acids, with a distinct structure that supports its function in calcium and bone metabolism. In humans, its amino acid sequence is H-Cys(1)-Gly-Asn-Leu-Ser-DL-Thr-Cys(1)-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2, featuring a seven-amino-acid ring at the N-terminus formed by a disulfide bond between cysteine residues at positions 1 and 7. This cyclic structure enhances the hormone’s stability and receptor-binding affinity. Calcitonin varies slightly across species, with salmon Calcitonin, often used therapeutically, sharing about 50% sequence homology with human Calcitonin but exhibiting greater potency due to structural differences. The hormone’s molecular weight is approximately 3417.9 g/mol, and its molecular formula is C151H226N40O45S3 in humans.

Pharmacologically, Calcitonin exerts its effects primarily on bone and kidney tissues to regulate calcium levels. It binds to G-protein-coupled receptors on osteoclasts, inhibiting their activity and reducing bone resorption, which lowers blood calcium levels. In the kidneys, Calcitonin enhances the excretion of calcium and phosphate through urine by acting on renal tubular cells. The hormone is administered therapeutically via nasal spray or injection, as oral administration is ineffective due to degradation in the gastrointestinal tract. After administration, Calcitonin is rapidly metabolized, primarily in the kidneys, with a plasma half-life typically ranging from 10-15 minutes and 50-80 minutes in humans. Its effects are most pronounced in conditions of elevated calcium or high bone turnover, such as osteoporosis or hypercalcemia. Salmon Calcitonin, due to its higher potency, is often preferred in clinical settings over human Calcitonin.

Dosages

Calcitonin is administered primarily through nasal spray or injection to manage conditions such as postmenopausal osteoporosis, Paget’s disease of bone, and hypercalcemia. Dosage regimens vary depending on the condition, route of administration, and the specific Calcitonin formulation, with salmon Calcitonin being the most commonly used due to its higher potency compared to human Calcitonin.

For postmenopausal osteoporosis, the typical dosage of salmon Calcitonin nasal spray is 200 international units (IU) delivered as one spray in one nostril daily. Patients are often advised to alternate nostrils each day to minimize irritation. Injectable salmon Calcitonin, when used for this condition, is typically administered at 100 IU daily or every other day via subcutaneous or intramuscular injection.

In the treatment of Paget’s disease of bone, injectable salmon Calcitonin is commonly prescribed at 50 to 100 IU daily or three times per week, depending on the severity of symptoms and patient response. Treatment may be adjusted over time as symptoms improve, often transitioning to a maintenance dose of 50 IU two to three times weekly.

For hypercalcemia, salmon Calcitonin is usually given via injection at a starting dose of 4 IU per kilogram of body weight every 12 hours, administered subcutaneously or intramuscularly. If needed, the dose may be increased to 8 IU per kilogram every 12 hours after 1 to 2 days, based on the patient’s calcium levels and clinical response.

Dosages should be tailored to patient needs, and administration typically involves calcium and vitamin D supplementation to support bone health, particularly in osteoporosis treatment. Patients using nasal spray should ensure proper technique to maximize absorption, while injectable forms require careful monitoring to avoid injection site reactions.

Warnings and Cautions

Calcitonin should be used with caution. Allergic reactions to this peptide, particularly salmon Calcitonin, have been reported. People with a history of hypersensitivity to fish products or Calcitonin should avoid its use. Symptoms such as rash, swelling, or difficulty breathing warrant immediate medical attention. A skin test may be recommended before starting injectable Calcitonin in patients with suspected sensitivity.

Nasal spray formulations may cause irritation or discomfort in the nasal passages. Users should monitor for signs of nasal ulcers, persistent congestion, or nosebleeds. Alternating nostrils daily during administration can help reduce irritation.

Long-term use of Calcitonin has been associated with a potential increase in malignancy risk in some studies, though data remain inconclusive. Patients with a history of cancer or those at higher risk should avoid using this peptide due to lack of information.

Calcitonin may lower blood calcium levels, potentially leading to hypocalcemia, especially in patients with low baseline calcium. Monitoring calcium levels is advisable, particularly during the early stages of treatment. Supplementation with calcium and vitamin D may be necessary to maintain adequate levels.

In patients with kidney or liver impairment, Calcitonin’s metabolism and clearance may be affected, requiring careful dose adjustments. Pregnant or breastfeeding women should use Calcitonin only if clearly needed, as its safety in these populations has not been fully established.

Injection site reactions, such as pain or redness, can occur with subcutaneous or intramuscular administration. Rotating injection sites and proper technique can minimize discomfort. Patients should report persistent or severe reactions.

Research & Trials

Calcitonin in MTC: Diagnostic Utility and Clinical Interpretation

This detailed review finds that calcitonin (CT), a hormone mainly made by certain cells in the thyroid, is an important marker for detecting a type of thyroid cancer called medullary thyroid carcinoma (MTC). However, high CT levels can also be caused by other health issues like different types of tumors, kidney problems, some medications, or even lab errors. While high baseline calcitonin levels (bCT), especially above 100 pg/ml, strongly point to MTC, they do not prove it by themselves. If CT levels are in the middle range (for example, 8–100 pg/ml in men and 6–80 pg/ml in women), doctors may do stimulation tests using calcium or a substance called pentagastrin, although the usefulness of these tests is now debated because more accurate CT tests are available.

If the CT level after stimulation is less than double the baseline level, MTC is less likely. CT levels also reflect how advanced the cancer is, helping doctors plan surgery and predict outcomes. A newer, more affordable method, measuring CT in the fluid from a fine needle biopsy (FNA-CT), shows promise in spotting cancer spread to lymph nodes. Although it’s rare, some people with MTC may have normal CT levels, possibly due to changes in the tumor or how it releases hormones.

Another substance, procalcitonin (ProCT), which comes before CT in the body’s production process, is also being studied to help tell the difference between MTC and infections. The question of if CT should be measured in everyone with thyroid lumps is still debated, but it’s clear that checking CT levels helps improve the accuracy of biopsy tests and is useful for tracking cancer before and after treatment. In summary, CT is still a key tool for diagnosing and managing MTC, but it needs to be interpreted carefully and in combination with other tests and clinical judgment. [1]

Dietary and Lifestyle Influences on Calcitonin Levels in Healthy Adults

The study concluded that calcitonin (CT) levels in healthy people are influenced by a range of sociodemographic, dietary, and lifestyle factors, with notable sex-specific differences, males showing higher CT levels than females. Positive associations were found between CT levels and age, BMI, and moderate alcohol intake (specifically white and red wine diluted with water). Interestingly, frequent consumption of white and blue fish, pasta, and rice was associated with higher CT levels, while butter, animal fat, and veal were associated with lower CT levels. Physical activity also played a role, with non-participants in sport showing higher CT levels compared to occasional participants. However, CT levels were not significantly associated with bone mineral density, weight, or body surface area. These findings underscore the complex and multifactorial regulation of CT, highlighting the importance of considering dietary habits, lifestyle, and demographic context in future hormonal and public health studies. [2]